Clinical trial
A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies
NCT00096980 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00096980 |
|---|---|
| Title | A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies |
| Official title | An Open Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneously Administered Efalizumab Used in Combination With Topical Psoriasis Therapies for Prolonged Maintenance Treatment |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Raptiva (efalizumab) |
| Enrollment | 300 |
| Start date | Feb 1, 2001 |
| Completion | May 1, 2004 |
| First posted | Nov 18, 2004 |
| Last update posted | Jun 21, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: